The Technical Analyst
Portage Biotech Inc. [PRTG]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Portage Biotech Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
11.07% $0.271
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5.36 mill |
| EPS: | -8.52 |
| P/E: | -0.0300 |
| Earnings Date: | Feb 28, 2024 |
| SharesOutstanding: | 19.78 mill |
| Avg Daily Volume: | 0.0865 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0300 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0300 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.654 (141.40%) $0.383 |
| Date: 2024-04-20 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.149 - 0.393 ( +/- 45.02%) |
| ATR Model: 14 days |
Forecast:
16:00 - $0.271
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.271
Forecast 2: 16:00 - $0.271
Forecast 3: 16:00 - $0.271
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.271 (11.07% ) |
| Volume | 0.300 mill |
| Avg. Vol. | 0.0865 mill |
| % of Avg. Vol | 347.14 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PRTG
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PRTG
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Latest Press Releases
2024-04-12 08:01:00 - Press Release
Portage Biotech Announces Plans To Expand Its Evaluation Of Strategic Alternatives
Westport, conn., april 12, 2024 (globe newswire) -- portage biotech inc. (nasdaq: prtg), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway.
2024-03-26 08:01:00 - Press Release
Portage Biotech Completes Monetization Of Intensity Therapeutics (ints) Shares
Company generated approximately $2.8m of non-dilutive funding to extend cash runway company generated approximately $2.8m of non-dilutive funding to extend cash runway
2024-02-28 17:10:00 - Press Release
Portage Biotech Reports Results For Fiscal Quarter Ended December 31, 2023, And Business Update
Portage biotech reports results for fiscal quarter ended december 31, 2023, and business update company focused on adenosine platform clinical development
2024-01-04 08:00:00 - Press Release
Portage Biotech Reports Business And Strategic Update
Westport, conn., jan. 04, 2024 (globe newswire) -- portage biotech inc. (nasdaq: prtg), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today announced the outcome from the company's comprehensive review of its pipeline in the context of the current capital raising market conditions.
2023-11-28 16:01:00 - Press Release
Portage Biotech Reports Results For Fiscal Quarter Ended June 30, 2023, And Business Update
Westport, conn., nov. 28, 2023 (globe newswire) -- portage biotech inc. (nasdaq: prtg), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended september 30, 2023.
Latest News
2023-09-20 08:00:00 - GlobeNewsWire
Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference
WESTPORT, Conn., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company's management team will participate in a panel discussion at the Cantor Global Healthcare Conference on Thursday, September 28, 2023 at 10:20 – 10:50 AM ET in New York, NY.
2023-01-26 09:02:25 - Zacks Investment Research
New Strong Buy Stocks for January 26th
FYBR, SPPJY, KMTUY, PRTG and ASML have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.
2023-01-20 07:32:04 - Zacks Investment Research
New Strong Buy Stocks for January 20th
NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.
2022-11-01 10:32:26 - Zacks Investment Research
New Strong Buy Stocks for November 1st
FFNW, PTEN, PRTG, NTNX and GAMB have been added to the Zacks Rank #1 (Strong Buy) List on November 1, 2022.
2022-08-01 11:37:59 - Zacks Investment Research
Does Portage Biotech Inc. (PRTG) Have the Potential to Rally 206% as Wall Street Analysts Expect?
The mean of analysts' price targets for Portage Biotech Inc. (PRTG) points to a 206.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2022-07-20 16:07:02 - Benzinga
Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform
Portage Biotech Inc (NASDAQ: PRTG) acquired the remaining 22% stake in its invariant natural killer T cell (iNKT agonist) platform and now wholly owns the worldwide rights to its small molecule iNKT agonists, including lead programs PORT-2 and PORT-3. The platform was acquired.
2021-11-22 16:53:00 - GlobeNewsWire
Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference
WESTPORT, Conn., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that Chief Executive Officer, Dr. Ian Walters, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021. Dr. Walters will give an overview of Portage's pipeline and status of current programs, including the company's lead invariant natural killer T cell (iNKT) agonists, PORT-2 and PORT-3.
2021-09-10 08:00:00 - GlobeNewsWire
Portage Biotech Announces Participation in September 2021 Investor Conferences
WESTPORT, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that as part of its commitment to investor outreach, management will be participating in the following investor conferences in September 2021.
2021-08-30 08:00:00 - GlobeNewsWire
Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year
2021-08-05 08:00:00 - GlobeNewsWire
Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)
WESTPORT, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the first patient has been dosed in the Oxford-led IMP-MEL study, a Phase 1/2, open-label, dose-escalation and randomized expansion clinical trial assessing the safety, tolerability and efficacy of PORT-2, a liposome formulation of the invariant natural killer T-cell (iNKT) agonist IMM60 developed for the treatment of solid tumors.